(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
A Centers for Disease Control and Prevention vaccine advisory committee meeting scheduled for next week — the first since ...
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
A panel of experts advising the U.S. Centers for Disease Control and Prevention on vaccines will not convene for its February ...
7d
Hosted on MSNGSK’s Penmenvy meningococcal vaccine gains FDA approvalThe studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results